Abstract
Executive Summary
This report aims to analyze the current and future potential of cancer
vaccines by examining key fundamentals across the entire pipeline of cancer
vaccine drug candidates. BioSeeker has identified three fundamental dimensions
to outline the competitive landscape within the pharmaceutical industry;
compound type, therapy area and target type. For the purposes of this report,
BioSeeker is focusing on therapeutic cancer vaccines and as such the
commercialized and pipeline prophylactic agents have not been included.
This report is written for you to identify your competition and understand
which targeting strategies are at work within cancer vaccine drug development.
It allows you to pin-point which competitors drugs' clinical out-come may have
bearing on your own drug development and who are developing sequels to
blockbuster drugs. This report also helps you to locate white-spots in the
competitive landscape, giving you little or no competition. Conversly it may
reveal unexpected competition for you.
Drug targets are the critical link between drugs and their role in the
treatment of medical disorders. BioSeeker has surveyed cancer vaccines and
identified 75 drug targets belonging to 109 drugs. This report, Cancer
Vaccine: Aim and Shoot, is an open landscape of resources to build, fuel, and
drive your scientific competitive vehicle for the advancement of cancer
vaccine drugs.
In the report, BioSeeker reports on 66 unique drug target combinations, each
comprised of a different collection or mix of individually defined targets,
for 109 cancer vaccine drugs designed for the treatment of 37 different cancer
indications. The highest degree of distinctiveness among cancer vaccine drugs
is achieved by sorting each of them according to targeted cancer indication,
drug target mix, and drug compound type. At the same time we are also
identifying peer groups of drugs, that is, drugs we consider suitable for
head-to-head comparison during drug development.
To fuel the scientific and competitive thinking, BioSeeker opens the gate into
the presence and relevance of protein-protein interactions between identified
targets of cancer vaccine drugs. No less than 64 protein-protein interactions
were recognized among and between 41 of the 75 included cancer vaccine drug
targets.
Why You Should Own Your Own Copy of this Report:
- 180+ pages, with almost a hundred different tables and figures. Includes
more than 1,000 active links to related resources on the Internet
- A 109 cancer vaccine drugs analysis, under development by 76
investigators, covering more than 236 developmental projects in cancer
- 75 unique, in-depth, drug target profiles, highlighting twelve themes
about the drug target, i.e. protein-protein interaction with other drug
targets, pursued cancer indications, drugs under development, compound types,
presence in the Cancer Genome Project etc.
- A unique drug target combination breakdown of cancer vaccines into tumor
type, compound type, and developmental stage
- Unique drug-protein target and protein-protein of drug targets interactome
analysis
- Pathway profiling of cancer vaccine drug targets
- Pin-point which competitor drugs' clinical out-come may have bearing on
your own drug development
- Who are working on sequels to blockbuster drugs?
- Locate white-spots in the competitive landscape, giving you little or no
competition
In all, this report is a serious reference for any professional interested in
the development of oncology drug targets and the selection/validation of
targeting strategies.
Pages: 184
Table of Contents
1. Executive Summary
2. About Cancer Highlights
3. Methodologies
4. Table of Contents
- 4.1 List of Figures
- 4.2 List of Tables
5. How to Use this Report
6. Cancer Vaccines Types
7. The Cancer Genome Project and Cancer Vaccine Drug Targets
- 7.1 Cancer Vaccine Drug Targets Present in the Cancer Gene Census and in the Catalogue Somatic Mutations in Cancer
8. Protein Expression Profiles of Cancer Vaccine Drug Targets in Human
- 8.1 Expression in Normal Tissues and Cancer Tissues
- 8.2 Expression in Human Cancer Cell Lines and Primary Cells
9. Pathway Analysis of Cancer Vaccine Drugs
10. Protein-Protein Interactions Among Identified Cancer Vaccine Drug Targets
11. Available Biological Structure Data on Cancer Vaccine Drug Targets
12. Drug Target Profiles of Cancer Vaccine Drug Targets in Oncology
- 12.1.1 Acid phosphatase activity
- 12.1.2 Carboxypeptidase activity
- 12.1.3 Catalytic activity
- 12.1.4 Cell adhesion molecule activity
- 12.1.5 Chaperone activity
- 12.1.6 Cofactor binding
- 12.1.7 Complement activity
- 12.1.8 Cytokine activity
- 12.1.9 DNA binding
- 12.1.10 DNA topoisomerase activity
- 12.1.11 DNA-directed DNA polymerase activity
- 12.1.12 Growth factor activity
- 12.1.13 Hormone activity
- 12.1.14 Hydrolase activity
- 12.1.15 Intracellular ligand-gated ion channel activity
- 12.1.16 Kinase binding
- 12.1.17 Kinase regulator activity
- 12.1.18 Metallopeptidase activity
- 12.1.19 MHC class I receptor activity
- 12.1.20 Molecular function unknown
- 12.1.21 Oxidoreductase activity
- 12.1.22 Peptidase activity
- 12.1.23 Peptide hormone
- 12.1.24 Protein binding
- 12.1.25 Protein serine/threonine kinase activity
- 12.1.26 Protein-tyrosine kinase activity
- 12.1.27 Receptor activity
- 12.1.28 Receptor binding
- 12.1.29 Receptor signaling complex scaffold activity
- 12.1.30 RNA-directed DNA polymerase activity
- 12.1.31 Serine-type peptidase activity
- 12.1.32 T cell receptor activity
- 12.1.33 Transcription factor activity
- 12.1.34 Transmembrane receptor activity
- 12.1.35 Transmembrane receptor protein tyrosine kinase activity
- 12.1.36 Transporter activity
- 12.1.37 Viral Protein
13. The Drug-Protein Interactome of Cancer Vaccines
14. The Progression and Maturity of Cancer Vaccine Drug Target Combinations
- 14.1 Target Profiles of Cancer Vaccines in Pre-Registration or on the Market
- 14.2 New Cancer Vaccine Target Combinations in Phase III Clinical Development
- 14.3 New Cancer Vaccine Target Combinations in Phase II Clinical Development
- 14.4 New Cancer Vaccine Target Combinations Phase I Clinical Development
- 14.5 New Cancer Vaccine Target Combinations in Preclinical Development
- 14.6 Development Profiles of All Identified Cancer VaccineTarget Combinations
15. Cancer Vaccine Drug Target Mix by Cancer Indication
- 15.1 Anal Dysplasia
- 15.2 Basal Cell Cancer
- 15.3 Bladder Cancer
- 15.4 Bone Cancer
- 15.5 Brain Cancer
- 15.6 Breast Cancer
- 15.7 Cervical Cancer
- 15.8 Cervical Dysplasia
- 15.9 Chemotherapy-Induced Bone Marrow Injury
- 15.9.1 Chemotherapy-Induced Neutropenia
- 15.10 Colorectal Cancer
- 15.11 Gastrointestinal Cancer
- 15.12 Head and Neck Cancer
- 15.13 Leukemia
- 15.13.1 Acute Myelogenous Leukemia
- 15.13.2 Chronic Lymphocytic Leukemia
- 15.13.3 Chronic Myelogenous Leukemia
- 15.14 Liver Cancer
- 15.15 Lung Cancer
- 15.15.1 Non-Small Cell Lung Cancer
- 15.15.2 Small Cell Lung Cancer
- 15.16 Lymphoma
- 15.16.1 B-Cell Lymphoma
- 15.16.2 Non-Hodgkin' s Lymphoma
- 15.16.3 T-Cell Lymphoma
- 15.17 Myelodysplastic Syndrome
- 15.18 Myeloma
- 15.19 Nasopharyngeal Cancer
- 15.20 Oesophageal Cancer
- 15.21 Ovarian Cancer
- 15.22 Pancreatic Cancer
- 15.23 Prostate Cancer
- 15.24 Renal Cancer
- 15.25 Sarcoma
- 15.26 Skin Cancer
- 15.27 Thyroid Cancer
16. Cancer Vaccine Drugs and Their Targets by Companies
- 16.1 Australia
- 16.2 Canada
- 16.3 China
- 16.4 Denmark
- 16.5 France
- 16.6 Germany
- 16.7 India
- 16.8 Israel
- 16.9 Italy
- 16.10 Japan
- 16.11 Netherlands
- 16.12 Norway
- 16.13 South Korea
- 16.14 Switzerland
- 16.15 United Kingdom
- 16.16 USA
- 16.17 Non-Industrial Bodies
17. Disclaimer
18. Drug Index
19. Company Index
4.1 List of Figures
- Figure 1: Distribution of Compound Types Among Cancer Vaccines
- Figure 2: Primary Sub-cellular Localization of Drug Targets
- Figure 3: Visualization of Protein-Protein Interactions Among Cancer
Vaccine Drug Targets
- Figure 4: The Vaccine-Protein Interactome of Cancer Vaccines
- Figure 5: Direct Head-to-Head Targeting Interactome of Cancer Vaccines
4.2 List of Tables
- Table 2: Drug Targets of Cancer Vaccines Present in the Catalogue of
Somatic Mutations in Cancer and in the Cancer Gene Census
- Table 3: Available Protein Expression Profiles of Cancer Vaccine Drug
Targets
- Table 4: Pathway Summary
- Table 5: Drug Targets Without any Identified Assigned Pathways
- Table 6: Pathway Profile According to BioCarta of Cancer Vaccine Targets
- Table 7: Pathway Profile According to KEGG of Cancer Vaccine Targets
- Table 8: Cancer Vaccines Targeting Major Singaling Pathways
- Table 9: Protein-Protein Interactions Among Cancer Vaccine Drug Targets
- Table 10: Number of Available Biological Structures on Cancer Vaccine
Targets
- Table 11: Overview of Drug Target Profile Themes
- Table 12: Vaccine-Protein Target Clusters in the Cancer Vaccine Drug
Target Interactome
- Table 13: Fall Out in Terms of the Total Number of Drug Target Mixes,
Drugs, Developmental Projects, and the Presence of New Drug Target Mixes by
Developmental Stage
- Table 14: Target Profiles of Cancer Vaccines in Pre-Registration or on the
Market
- Table 15: New Cancer Vaccine Drug Target Combinations in Phase III
Clinical Development
- Table 16: New Cancer Vaccine Target Combinations in Phase II Clinical
Development
- Table 17 New Cancer Vaccine Target Combinations Phase I Clinical
Development
- Table 18: New Cancer Vaccine Target Combinations in Preclinical Development
- Table 19: Top 5 Pursued Cancer Vaccine Targets
- Table 20: The Progression, Maturity and Comptitive Comparison of Cancer
Vaccine Target Mixes in Development
- Table 21: Number of Cancer Vaccine Drug Target Mixes Reported by Cancer
Indication
- Table 22: Locating Your Competitors/Peers - Step 1
- Table 23: Locating Your Competitors/Peers - Step 2
- Table 24: Drug Targets of Cancer Vaccines for the Treatment of Anal
Dysplasia According to the Compound Type and Developmental Stage of Vaccine
- Table 25: Drug Targets of Cancer Vaccines for the Treatment of Basal Cell
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 26: Drug Targets of Cancer Vaccines for the Treatment of Bladder
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 27: Drug Targets of Cancer Vaccines for the Treatment of Bone Cancer
According to the Compound Type and Developmental Stage of Vaccine
- Table 28: Drug Targets of Cancer Vaccines for the Treatment of Brain
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 29: Drug Targets of Cancer Vaccines for the Treatment of Breast
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 30: Drug Targets of Cancer Vaccines for the Treatment of Cervical
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 31: Drug Targets of Cancer Vaccines for the Treatment of Cervical
Dysplasia According to the Compound Type and Developmental Stage of Vaccine
- Table 32: Drug Targets of Cancer Vaccines for the Treatment of
Chemotherapy-Induced Bone Marrow Injury (General) According to the Compound
Type and Developmental Stage of Vaccine
- Table 33: Drug Targets of Cancer Vaccines for the Treatment of
Chemotherapy-Induced Neutropenia According to the Compound Type and
Developmental Stage of Vaccine
- Table 34: Drug Targets of Cancer Vaccines for the Treatment of Colorectal
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 35: Drug Targets of Cancer Vaccines for the Treatment of
Gastrointestinal Cancer According to the Compound Type and Developmental Stage
of Vaccine
- Table 36: Drug Targets of Cancer Vaccines for the Treatment of Head and
Neck Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 37: Drug Targets of Cancer Vaccines for the Treatment of Leukemia
(General) According to the Compound Type and Developmental Stage of Vaccine
- Table 38: Drug Targets of Cancer Vaccines for the Treatment of Acute
Myelogenous Leukemia According to the Compound Type and Developmental Stage of
Vaccine
- Table 39: Drug Targets of Cancer Vaccines for the Treatment of Chronic
Lymphocytic Leukemia According to Compound Type and Developmental Stage of
Vaccine
- Table 40: Drug Targets of Cancer Vaccines for the Treatment of Chronic
Myelogenous Leukemia According to the Compound Type and Developmental Stage of
Vaccine
- Table 41: Drug Targets of Cancer Vaccines for the Treatment of Liver
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 42: Drug Targets of Cancer Vaccines for the Treatment of Lung Cancer
(General) According to the Compound Type and Developmental Stage of Vaccine
- Table 43: Drug Targets of Cancer Vaccines for the Treatment of Non Small
Cell Lung Cancer According to the Compound Type and Developmental Stage of
Vaccine
- Table 44 Drug Targets of Cancer Vaccines for the Treatment of Small Cell
Lung According to the Compound Type and Developmental Stage of Vaccine
- Table 45: Drug Targets of Cancer Vaccines for the Treatment of Lymphoma
(General) According to the Compound Type and Developmental Stage of Vaccine
- Table 46: Drug Targets of Cancer Vaccines for the Treatment of B-Cell
Lymphoma According to the Compound Type and Developmental Stage of Vaccine
- Table 47: Drug Targets of Cancer Vaccines for the Treatment of
non-Hodgkin' s Lymphoma According to the Compound Type and Developmental Stage
of Vaccine
- Table 48: Drug Targets of Cancer Vaccines for the Treatment of T-Cell
Lymphoma According to the Compound Type and Developmental Stage of Vaccine
- Table 49: Drug Targets of Cancer Vaccines for the Treatment of
Myelodysplastic Syndrome According to the Compound Type and Developmental
Stage of Vaccine
- Table 50: Drug Targets of Cancer Vaccines for the Treatment of Myeloma
According to the Compound Type and Developmental Stage of Vaccine
- Table 51: Drug Targets of Cancer Vaccines for the Treatment of
Nasopharyngeal Cancer According to the Compound Type and Developmental Stage
of Vaccine
- Table 52: Drug Targets of Cancer Vaccines for the Treatment of Oesophageal
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 53: Drug Targets of Cancer Vaccines for the Treatment of Ovarian
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 54: Drug Targets of Cancer Vaccines for the Treatment of Pancreatic
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 55: Drug Targets of Cancer Vaccines for the Treatment of Prostate
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 56: Drug Targets of Cancer Vaccines for the Treatment of Renal
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 57: Drug Targets of Cancer Vaccines for the Treatment of Sarcoma
According to the Compound Type and Developmental Stage of Vaccine
- Table 58: Drug Targets of Cancer Vaccines for the Treatment of Skin Cancer
According to the Compound Type and Developmental Stage of Vaccine
- Table 59: Drug Targets of Cancer Vaccines for the Treatment of Melanoma
According to the Compound Type and Developmental Stage of Vaccine
- Table 60: Drug Targets of Cancer Vaccines for the Treatment of Thyroid
Cancer According to the Compound Type and Developmental Stage of Vaccine
- Table 61: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Australia
- Table 62: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Canada
- Table 63: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in China
- Table 64: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Denmark
- Table 65: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in France
- Table 66: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Germany
- Table 67: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in India
- Table 68: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Israel
- Table 69: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Italy
- Table 70: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Japan
- Table 71: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in the Netherlands
- Table 72: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Norway
- Table 73: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in South Korea
- Table 74: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in Switzerland
- Table 75: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in United Kingdom
- Table 76: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Companies in USA
- Table 77: Cancer Vaccines with Drug Target Mix and Developmental Projects
by Non-Industrial Bodies
医薬品
その他のカテゴリ
FAQ